A 24-week, Phase III, Open-label, Non-comparative, Multi-center Study to Evaluate Efficacy and Safety of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Daprodustat (Primary) ; Iron
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 28 Nov 2016 Status changed from not yet recruiting to recruiting.
- 29 Jul 2016 Planned initiation date changed from 1 Jul 2016 to 1 Aug 2016.